Renaissance Technologies (RenTech)'s FULC Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 13,600 shares of Fulcrum Therapeutics, Inc. (FULC) worth $104,312, representing 0.00% of the portfolio. First purchased in 2021-Q3, this medium-term investment has been held for 15 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in FULC, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 401,100 shares. Largest reduction occurred in Q2 2025, reducing 322,600 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Fulcrum Therapeutics (FULC) Holding Value Over Time
Track share changes against reported price movement
Quarterly Fulcrum Therapeutics (FULC) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -3,800 | Reduce 21.84% | 13,600 | $7.67 |
| Q4 2025 | -230,800 | Reduce 92.99% | 17,400 | $11.31 |
| Q3 2025 | +169,700 | Add 216.18% | 248,200 | $9.20 |
| Q2 2025 | -322,600 | Reduce 80.43% | 78,500 | $6.88 |
| Q1 2025 | +401,100 | New Buy | 401,100 | $2.88 |
| Q3 2024 | -13,257 | Sold Out | 0 | $0.00 |
| Q2 2024 | +13,257 | New Buy | 13,257 | $6.20 |
| Q4 2023 | -52,734 | Sold Out | 0 | $0.00 |
| Q3 2023 | -292,076 | Reduce 84.71% | 52,734 | $4.44 |
| Q2 2023 | -45,290 | Reduce 11.61% | 344,810 | $0.00 |
| Q1 2023 | +390,100 | New Buy | 390,100 | $0.00 |
| Q3 2022 | -68,000 | Sold Out | 0 | $0.00 |
| Q2 2022 | +68,000 | New Buy | 68,000 | $4.90 |
| Q4 2021 | -133,900 | Sold Out | 0 | $0.00 |
| Q3 2021 | +133,900 | New Buy | 133,900 | $28.21 |
Renaissance Technologies (RenTech)'s Fulcrum Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Fulcrum Therapeutics, Inc. (FULC) in Q3 2021, acquiring 133,900 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Fulcrum Therapeutics, Inc. (FULC) for 15 quarters since Q3 2021.
Renaissance Technologies (RenTech)'s largest addition to Fulcrum Therapeutics, Inc. (FULC) was in Q1 2025, adding 401,100 shares worth $1.16 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 13,600 shares of Fulcrum Therapeutics, Inc. (FULC), valued at approximately $104,312.
As of the Q1 2026 filing, Fulcrum Therapeutics, Inc. (FULC) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Fulcrum Therapeutics, Inc. (FULC) was 401,100 shares, as reported at the end of Q1 2025.